Appili Therapeutics Inc (APLI) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.018x

Based on the latest financial reports, Appili Therapeutics Inc (APLI) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-293.07K ≈ $-212.00K USD) by net assets (CA$-16.38 Million ≈ $-11.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Appili Therapeutics Inc worth for the company's overall valuation and market capitalisation.

Appili Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Appili Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Appili Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Appili Therapeutics Inc ranked by their cash flow conversion efficiency. Explore APLI cash flow quality score to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Companhia Tecidos Santanense Ltda SA:CTSA3	0.074x
Schroder European Reit Plc LSE:SERE	0.022x
Inti Kapuas Arowana Tbk JK:IIKP	-0.003x
Science in Sport plc LSE:SIS	0.025x
CT Global Managed Portfolio Trust PLC LSE:CMPI	0.010x
Alveen PA:MLALV	N/A
Ribbon Acquisition Corp Rights NASDAQ:RIBBR	N/A
FKS Food Sejahtera Tbk PT JK:AISA	0.005x

Annual Cash Flow Conversion Efficiency for Appili Therapeutics Inc (2017–2025)

The table below shows the annual cash flow conversion efficiency of Appili Therapeutics Inc from 2017 to 2025. View today's stock price for Appili Therapeutics Inc for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	CA$-13.40 Million ≈ $-9.69 Million	CA$868.82K ≈ $628.49K	-0.065x	-128.75%
2024-03-31	CA$-10.92 Million ≈ $-7.90 Million	CA$-2.46 Million ≈ $-1.78 Million	0.226x	-83.48%
2023-03-31	CA$-7.40 Million ≈ $-5.35 Million	CA$-10.10 Million ≈ $-7.30 Million	1.365x	-76.60%
2022-03-31	CA$-3.27 Million ≈ $-2.37 Million	CA$-19.08 Million ≈ $-13.80 Million	5.834x	+749.77%
2021-03-31	CA$12.75 Million ≈ $9.23 Million	CA$-11.45 Million ≈ $-8.28 Million	-0.898x	-86.42%
2020-03-31	CA$8.85 Million ≈ $6.40 Million	CA$-4.26 Million ≈ $-3.08 Million	-0.482x	+38.42%
2019-03-31	CA$4.42 Million ≈ $3.20 Million	CA$-3.46 Million ≈ $-2.50 Million	-0.782x	-15.22%
2018-03-31	CA$4.87 Million ≈ $3.52 Million	CA$-3.30 Million ≈ $-2.39 Million	-0.679x	+56.34%
2017-03-31	CA$1.37 Million ≈ $994.41K	CA$-2.14 Million ≈ $-1.55 Million	-1.555x	--

About Appili Therapeutics Inc

TO:APLI Canada Biotechnology

Market Cap

$928.58K

CA$1.28 Million CAD

Market Cap Rank

#30748 Global

#1593 in Canada

Share Price

CA$0.01

Change (1 day)

-33.33%

52-Week Range

CA$0.01 - CA$0.04

All Time High

CA$1.87